Skip to main content

COVID19: Structure of COVID19 SARS-CoV-2 Spike protein in complex with monoclonal antibodies.


EMSL Project ID
51528

Abstract

The ongoing global outbreak of atypical pneumonia (COVID-19) is caused by a newly emerged zoonotic beta coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). On March 11th, 2020, the World Health Organization declared COVID-19 a pandemic (2) and as of April 30th, 2020, over 3 M people were estimated to have been infected and over 200, 000 people had died (3). There is currently no vaccine available to prevent infection with SARS-CoV-2 or therapeutics. It is also unclear which types of immune responses are required to prevent or control infection. Our team has isolated monoclonal antibodies from infected COVID-19 patients. The goal of this project is to identify critical sites of vulnerability on SARS-CoV-2 S glycoproteins through structure/function analyses of monoclonal antibodies developed during natural infection. Such antibodies can be employed as preventive or therapeutic agents. Moreover, structurally defining critical sites of vulnerability on SARS-CoV-2 will facilitate the development of an effective vaccine against this pathogen.

Project Details

Start Date
2020-06-27
End Date
2021-03-17
Status
Closed

Team

Principal Investigator

Marie Pancera
Institution
Fred Hutchinson Cancer Research Center

Team Members

Nicholas Hurlburt
Institution
Fred Hutchinson Cancer Research Center

Justas Rodarte
Institution
Fred Hutchinson Cancer Research Center

Theo Humphreys
Institution
Oregon Health & Science University

Suruchi Singh
Institution
Fred Hutchinson Cancer Research Center

Irina El Khoury
Institution
Environmental Molecular Sciences Laboratory